Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell 1Lymphoma, Mantle-Cell 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma 1Burkitt Lymphoma 1

Interventions

fludarabine phosphate 6Rituximab 5Antilymphocyte Serum 5Tacrolimus 4Cyclophosphamide 4pegaspargase 3Whole-Body Irradiation 3Radiotherapy, Intensity-Modulated 3Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Oxaliplatin 3Mycophenolic Acid 3Etoposide 3Dasatinib 3Vincristine 2Melphalan 2Lenalidomide 2Gemcitabine 2Filgrastim 2Doxorubicin 2Busulfan 2tislelizumab 1thymoglobulin 1tanespimycin 1plerixafor 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1obatoclax 1gemcitabine-oxaliplatin regimen 1etoposide phosphate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoma, Extranodal NK-T-Cell × Loratadine × Clear all
NCT02392039 2019-04-23

Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma

M.D. Anderson Cancer Center

Phase EARLY_PHASE1 Terminated
1 enrolled
Lymphoid

Burkitt Lymphoma, Lymphoma, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡